Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies

Acta Psychiatrica Scandinavica

Volumn 135, Issue 5, 2017, Pages 373-387

  Kohler C A ^a   Freitas, T H ^a   Maes, M ^b,c,d,e,f   de Andrade, N Q ^a   Liu, C S ^g,h   Fernandes, B S ^b,i   Stubbs, B ^j,k   Solmi, M ^l,m   Veronese, N ^l   Herrmann, N ^g,h   Raison, C L ^n,o   Miller, B J ^p   Lanctot K L ^g,h   Carvalho, A F ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b DEAKIN UNIVERSITY   (Australia)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d STATE UNIVERSITY OF LONDRINA   (Brazil)

^e MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

^f Revitalis   (Netherlands)

^g UNIVERSITY OF TORONTO   (Canada)

^h Sunnybrook Health Sciences Centre   (Canada)

ⁱ FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^j SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF PADOVA   (Italy)

^m Institute of Clinical Research and Education in Medicine (IREM)   (Italy)

ⁿ UNIVERSITY OF WISCONSIN MADISON   (United States)

^o UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^p MEDICAL COLLEGE OF GEORGIA   (United States)

more..

Author keywords

chemokines; cytokines; depression; inflammation; meta analysis

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

AGE; ARTICLE; BODY MASS; DISEASE ASSOCIATION; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; SMOKING; SYSTEMATIC REVIEW; FEMALE; IMMUNOLOGY; MALE; META ANALYSIS; METABOLISM;

CHEMOKINES; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE;

EID: 85017002844     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12698     Document Type: Article

References (76)

1. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:11–38.
2. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2016;16:22–34.
3. Haroon E, Fleischer CC, Felger JC et al. Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Mol Psychiatry 2016;21:1351–1357.
4. Wohleb ES, Franklin T, Iwata M, Duman RS. Integrating neuroimmune systems in the neurobiology of depression. Nat Rev Neurosci 2016;17:497–511.
5. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimaki M. Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 2015;49:206–215.
6. Maes M, Scharpe S, van Grootel L et al. Higher alpha 1-antitrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: further evidence for the existence of an inflammatory response during that illness. J Affect Disord 1992;24:183–192.
7. Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446–457.
8. Stuart MJ, Baune BT. Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci Biobehav Rev 2014;42:93–115.
9. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46–56.
10. Simen BB, Duman CH, Simen AA, Duman RS. TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry 2006;59:775–785.
11. Chourbaji S, Urani A, Inta I et al. IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. Neurobiol Dis 2006;23:587–594.
12. Udina M, Castellvi P, Moreno-Espana J et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 2012;73:1128–1138.
13. Thase ME. Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies. Dialogues Clin Neurosci 2014;16:539–544.
14. Carvalho AF, Kohler CA, Brunoni AR et al. Bias in peripheral depression biomarkers. Psychother Psychosom 2016;85:81–90.
15. Gold PW. The organization of the stress system and its dysregulation in depressive illness. Mol Psychiatry 2015;20:32–47.
16. Lamers F, Vogelzangs N, Merikangas KR, de Jonge P, Beekman AT, Penninx BW. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry 2013;18:692–699.
17. Stuart MJ, Singhal G, Baune BT. Systematic review of the neurobiological relevance of chemokines to psychiatric disorders. Frontiers Cellular Neurosci 2015;9:357.
18. Sochocka M, Diniz BS, Leszek J. Inflammatory response in the CNS: friend or foe? Mol Neurobiol 2016. doi: 10.1007/s12035-016-0297-1 [Epub ahead of print].
19. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71:171–186.
20. Hiles SA, Baker AL, de Malmanche T, Attia J. A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behav Immun 2012;26:1180–1188.
21. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
22. Bakkalbasi N, Bauer K, Glover J, Wang L. Three options for citation tracking: Google Scholar, Scopus and Web of Science. Biomed Digit Libr 2006;3:7.
23. ASSOCIATION AP. DSM 5. American Psychiatric Association; 2013.
24. ORGANIZATION WH. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research; 1993.
25. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
26. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820–826.
27. Patsopoulos NA, Evangelou E, Ioannidis JP. Heterogeneous views on heterogeneity. Int J Epidemiol 2009;38:1740–1742.
28. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188.
29. Carvalho AF, Kohler CA, Fernandes BS et al. Bias in emerging biomarkers for bipolar disorder. Psychol Med 2016;46:2287–2297.
30. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–634.
31. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–463.
32. Rosenthal R. The file drawer problem and tolerance for null results. Psychol Bull 1979;86:638.
33. Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med 2004;23:1663–1682.
34. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559–1573.
35. Krogh J, Benros ME, Jorgensen MB, Vesterager L, Elfving B, Nordentoft M. The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain Behav Immun 2014;35:70–76.
36. O'Donovan A, Rush G, Hoatam G et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety 2013;30:307–314.
37. Dunjic-Kostic B, Ivkovic M, Radonjic NV et al. Melancholic and atypical major depression–connection between cytokines, psychopathology and treatment. Prog Neuropsychopharmacol Biol Psychiatry 2013;43:1–6.
38. Elderkin-Thompson V, Irwin MR, Hellemann G, Kumar A. Interleukin-6 and memory functions of encoding and recall in healthy and depressed elderly adults. Am J Geriatr Psychiatry 2012;20:753–763.
39. Kahl KG, Bester M, Greggersen W et al. Visceral fat deposition and insulin sensitivity in depressed women with and without comorbid borderline personality disorder. Psychosom Med 2005;67:407–412.
40. Motivala SJ, Sarfatti A, Olmos L, Irwin MR. Inflammatory markers and sleep disturbance in major depression. Psychosom Med 2005;67:187–194.
41. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001;11:203–208.
42. Maes M, Bosmans E, de Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997;9:853–858.
43. Maes M, Meltzer HY, Bosmans E et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995;34:301–309.
44. Leo R, di Lorenzo G, Tesauro M et al. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry 2006;67:1760–1766.
45. Shen Y, Lu P, Wei L, Hu X, Chen W. Fluoxetine treatment for major depression decreases the plasma levels of cytokines. Afr J Biotechnol 2010;9:7346–7351.
46. Schmidt FM, Lichtblau N, Minkwitz J et al. Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity. J Psychiatr Res 2014;55:29–34.
47. Kaestner F, Hettich M, Peters M et al. Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J Affect Disord 2005;87:305–311.
48. Ho PS, Yeh YW, Huang SY, Liang CS. A shift toward T helper 2 responses and an increase in modulators of innate immunity in depressed patients treated with escitalopram. Psychoneuroendocrinology 2015;53:246–255.
49. Papakostas GI, Shelton RC, Kinrys G et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol Psychiatry 2013;18:332–339.
50. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 2016;21:1696–1709.
51. Kessler RC, Merikangas KR, Wang PS. Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Ann Rev Clin Psychol 2007;3:137–158.
52. Vancampfort D, Correll CU, Wampers M et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol Med 2014;44:2017–2028.
53. Du YJ, Yang CJ, Li B et al. Association of pro-inflammatory cytokines, cortisol and depression in patients with chronic obstructive pulmonary disease. Psychoneuroendocrinology 2014;46:141–152.
54. Mansur RB, Brietzke E, McIntyre RS. Is there a “metabolic-mood syndrome”? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev 2015;52:89–104.
55. Capuron L, Lasselin J, Castanon N. Role of adiposity-driven inflammation in depressive morbidity. Neuropsychopharmacology 2017;42:115–128.
56. Liu CS, Carvalho AF, McIntyre RS. Towards a “metabolic” subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction. CNS Neurol Disord Drug Targets 2014;13:1693–1707.
57. Berk M, Williams LJ, Jacka FN et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013;11:200.
58. Maes M, Anderson G, Kubera M, Berk M. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin Ther Targets 2014;18:495–512.
59. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65:732–741.
60. Horowitz MA, Zunszain PA, Anacker C, Musaelyan K, Pariante CM. Glucocorticoids and inflammation: a double-headed sword in depression? How do neuroendocrine and inflammatory pathways interact during stress to contribute to the pathogenesis of depression? Mod Trends Pharmacopsychiat 2013;28:127–143.
61. Maes M, Scharpe S, Meltzer HY et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994;54:143–160.
62. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Cytokine production and serum proteins in depression. Scand J Immunol 1995;41:534–538.
63. Smith RS. The macrophage theory of depression. Med Hypotheses 1991;35:298–306.
64. Kalkman HO, Feuerbach D. Antidepressant therapies inhibit inflammation and microglial M1-polarization. Pharmacol Ther 2016;163:82–93.
65. Yirmiya R, Rimmerman N, Reshef R. Depression as a microglial disease. Trends Neurosci 2015;38:637–658.
66. Wohleb ES, McKim DB, Sheridan JF, Godbout JP. Monocyte trafficking to the brain with stress and inflammation: a novel axis of immune-to-brain communication that influences mood and behavior. Frontiers Neurosci 2014;8:447.
67. Mills CD. Anatomy of a discovery: m1 and m2 macrophages. Front Immunol 2015;6:212.
68. Nathan C. Points of control in inflammation. Nature 2002;420:846–852.
69. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133:775–787.
70. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010;10:490–500.
71. Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med 2011;73:114–126.
72. Black C, Miller BJ. Meta-Analysis of Cytokines and Chemokines in Suicidality: distinguishing Suicidal Versus Nonsuicidal Patients. Biol Psychiatry 2015;78:28–37.
73. Eller T, Vasar V, Shlik J, Maron E. The role of IL-2 and soluble IL-2R in depression and antidepressant response. Curr Opin Investig Drugs 2009;10:638–643.
74. Slyepchenko A, Maes M, Kohler CA et al. T helper 17 cells may drive neuroprogression in major depressive disorder: proposal of an integrative model. Neurosci Biobehav Rev 2016;64:83–100.
75. Beurel E, Harrington LE, Jope RS. Inflammatory T helper 17 cells promote depression-like behavior in mice. Biol Psychiatry 2013;73:622–630.
76. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009;27:485–517.